Lilly’s retatrutide beats Ozempic in a diabetes trial (not approved) Lilly announced that its investigational once-weekly drug retatrutide, tested against Ozempic 2 mg in 1,298 adults with type 2 diabetes, led to average weight loss of 19.5% (9 mg) and 20.9% (12 mg) at 80 weeks, versus 9.4% on Ozempic. A1C fell 2.2 points versus
The short answer: Early, company-sponsored analyses suggest that semaglutide and tirzepatide nudge some blood-based “aging clock” readings in a younger direction in people with obesity, heart disease or diabetes. These results are not peer reviewed, none of them tested healthy people, and a better clock reading has not been shown to mean a longer or
Bottom Line On October 28, 2026, Eli Lilly announced topline results from TRANSCEND-T2D-2, a Phase 3 trial of 1,298 adults with type 2 diabetes. After 80 weeks, people taking its investigational drug retatrutide lost about 19.5% (9 mg dose) to 20.9% (12 mg dose) of their body weight and lowered HbA1C by 2.2 percentage points,
A short guide to three stories from this month, explained simply Three stories about GLP-1 medicines got a lot of attention this month. We wrote a full article on each one. This guide gives you the main points in plain language. Each section links to the full article if you want more detail. 1. GLP-1
This Week in Obesity Medicine A Phase 2 trial of petrelintide, a once-weekly amylin drug, showed up to about 10% weight loss at 42 weeks with modest nausea (about 20% vs 6% on placebo). It is not approved, has not been compared directly with GLP-1 drugs, and is in Phase 3. Novo Nordisk’s first real-world
Bottom Line Novo Nordisk reported at the 2026 European Association for the Study of Diabetes meeting that 194 people who switched from weekly injections to the Wegovy pill lost an average of an additional 4.1% of body weight over three months. That is a useful signal that many people do not regain on the pill,
